Follow Us
Member Of
Incontinence and Bladder Studies
Study: Vicinium
Efficacy testing of Vicinium in bladder cancer patients previously treated with BCG.
Indication:
Bladder Cancer
Key Points:
Study is open label, so all eligible patients receive medication.
Who?
Recurrence with higher grades TCCa after 5 induction BCG and 2 maintenance BCG.
Study: Spectrum
Study of Surgical adjuvant post-operative to TURBT
Indication:
Bladder Cancer
Key Points:
Eligible patients may receive medication or placebo.
Who?
Patients who have low grade bladder tumors with negative cytology.
Study: Ipsen
Evaluating Dysport for the treatment of urinary incontinence in subjects with neurogenic detrusor overactivity due to spinal cord injury or multiple sclerosis
Indication:
Urinary Incontinence
Key Points:
Eligible patients may receive either medication or placebo initially for 1st treatment, but receive the medication 12 weeks after the first treatment.
Who?
MS or SCI, on SIC with persistent incontinence despite OAB meds (antimuscarinic or β-3 agonists).
Study: Adelphi
Pain and quality of life survey of individuals with advanced bladder cancer
Indication:
Bladder Cancer
Key Points:
Observational study
Who?
Advanced bladder cancer: metastatic, node progression or T4b, or patients being sent for chemotherapy or radiation.
Study: Aquinox
Efficacy and safety of AQX-1125 (oral tablet) in reducing bladder pain from Interstitial cystitis
Indication:
Interstitial Cystitis (IC)
Key Points:
Eligible patient may receive medication or placebo
Who?
Bladder pain and interstitial cystitis. Experiencing moderate to severe symptoms.
Study: Astellas
Evaluating a drug (myrbetriq) for OAB in patients with BPH who are already taking tamsulosin
Indication:
Overactive Bladder & Benign Prostatic Hyperplasia (BPH)
Key Points:
Patient may receive myrbetriq or placebo.
Who?
Men with BPH and persistent OAB despite taking tamsulosin.